 |
|
|
|
|
|
|
| Article 1 to 10 out of 31 concerning Eli Lilly and Company
|
-
Scandal in the Pharmaceutical World
(30 Jun 2008)
A large number of the world's largest pharmaceutical companies have illegally used, and profited from, a groundbreaking patent stolen from Nogdan Immunochemicals Ltd., an Israeli biotech company
Nogdan Immunochemicals Ltd.and Mr. Roland Taieb, the exclusive owner of the patent's marketing rights worldwide, announced that many of the world's largest pharmaceutical companies are embroiled in the legal dispute concerning their groundbreaking ...
-
CMC Acquires Former ICOS Biologics Operation in Bothell, Washington State, USA
(05 Dec 2007)
CMC Biopharmaceuticals to purchase facility from Lilly; will retain existing employees
CMC Biopharmaceuticals A/S (CMC) announced that it has reached an agreement to buy the biologics development and manufacturing operation that Eli Lilly and Company acquired when it purchased ICOS Corporation in January 2007. CMC, a Copenhagen based ...
-
Lilly Announces New Employee Policy
(11 May 2007)
Privacy and protection of genetic information essential for improved patient care
Eli Lilly and Company announced an expansion of its employee policies to include protection of genetic information. This addition to Lilly's privacy and nondiscrimination policies ensures an employee's genetic information cannot be used to ...
-
Lilly Announces Acquisition of Hypnion
(07 Mar 2007)
Deal shall bolster Lilly's Sleep Disorder Research with promising insomnia compound
Eli Lilly and Company and Hypnion, Inc. announced that they have signed a definitive merger agreement whereby Lilly will acquire Hypnion, a privately held neuroscience drug discovery company focused on sleep disorders. The transaction has received ...
-
ICOS Shareholders Vote to Approve Merger With Eli Lilly
(29 Jan 2007)
ICOS Corporation (ICOS) announced that its shareholders approved the revised Agreement and Plan of Merger whereby Eli Lilly and Company will acquire all of the outstanding stock of ICOS for a purchase price of $34 per share in cash.There was a ...
-
Alkermes and Lilly Expand AIR Inhaled Insulin Collaboration
(10 Jan 2007)
Alkermes, Inc. and Eli Lilly and Company announced that they have signed a commercial manufacturing agreement for AIRŪ Inhaled Insulin (AIRŪ Insulin). As a result of the agreement, Alkermes will be the exclusive commercial manufacturer of AIR ...
-
ICOS Announces Revised Merger Agreement With Lilly
(20 Dec 2006)
ICOS Corporation announced that an agreement has been reached to amend the terms of the merger agreement with Eli Lilly and Company, which was originally signed on October 16, 2006. The revised Agreement and Plan of Merger provides that Lilly will ...
-
Lilly acquires ICOS Corporation for $2.1 Billion
(19 Oct 2006)
Eli Lilly and Company announced that it has signed a definitive merger agreement to acquire ICOS Corporation in a cash transaction. Under the terms of the agreement, Lilly will acquire all of the outstanding shares of ICOS common stock at a price of ...
-
Oncology Researchers Recognized as Heroes of Chemistry
(13 Sep 2006)
American Chemical Society Honors Lilly and Princeton Scientists for Discovery of Therapy for Asbestos-Related Cancer
Three researchers who led the discovery and development of the first drug approved to treat malignant pleural mesothelioma (MPM), a cancer associated with exposure to asbestos, were named as Heroes of Chemistry by the American Chemical Society ...
-
Alkermes and Lilly Announce Agreement for the Development and Commercialization of Inhaled Parathyroid Hormone
(11 Jan 2006)
Alkermes, Inc. and Eli Lilly and Company announced that they have signed an agreement to develop and commercialize inhaled formulations of parathyroid hormone (PTH). The development program will utilize the Alkermes AIRŪ pulmonary drug delivery ...
|
|
|
|
|
Top